Gene · 2042
EPHA3: EPH receptor A3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. EPHA3: EPH receptor A3. Genes, record 2042. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2042
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P29320 | Ephrin type-A receptor 3 | 983 | 28 | Ensembl, GeneID, HGNC |
Source UniProt
Patents93
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| US 12636345 B2 | 2026-05-26 | 56 | P29320 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 45079 | P29320 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 6281 | P29320 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 6043 | P29320 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 4806 | P29320 | Espacenet |
| WO 2025194019 A1 | 2025-09-18 | 2 | P29320 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1414 | P29320 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6272 | P29320 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1414 | P29320 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 6272 | P29320 | Espacenet |
1 to 10 of 93
See all 93 patentsDrugs2
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
Trials99
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06482086 | VANDETANIB | PHASE2 | ClinicalTrials.gov | |
| NCT04211337 | VANDETANIB | PHASE3 | 2024-06-13 | ClinicalTrials.gov |
| NCT03630120 | VANDETANIB | PHASE2 | 2021-01-22 | ClinicalTrials.gov |
| NCT03374943 | KB-004 | PHASE1 | ClinicalTrials.gov | |
| NCT03291379 | VANDETANIB | EARLY_PHASE1 | 2021-02-03 | ClinicalTrials.gov |
| NCT02638428 | VANDETANIB | PHASE2 | ClinicalTrials.gov | |
| NCT02530411 | VANDETANIB | PHASE2 | ClinicalTrials.gov | |
| NCT02495103 | VANDETANIB | PHASE1/PHASE2 | 2021-01-26 | ClinicalTrials.gov |
| NCT02299999 | VANDETANIB | PHASE2 | ClinicalTrials.gov | |
| NCT02117167 | VANDETANIB | PHASE2 | ClinicalTrials.gov |
1 to 10 of 99
See all 99 trialsNIH grants1,326
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | EPHA3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 24 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 12 | 2025 |
| R35GM118062 | Integrating Chemistry and Evolution to Illuminate Biology and Enable Novel Therapeutics | 11 | 2025 |
| RM1HG009490 | Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human Disease | 11 | 2025 |
| P30CA012197 | Cancer Center Support Grant | 7 | 2025 |
| P30CA030199 | Cancer Center Support Grant (CCSG) | 6 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 5 | 2025 |
| T32CA009592 | Microenvironmental Influences in Cancer | 5 | 2025 |
| ZIABC010441 | Biomolecular Recognition and Binding Mechanisms | 5 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 4 | 2025 |
1 to 10 of 1,326Source NIH's project files
See all 1,326 nih grantsPapers1,673
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| EPHA3, upregulated in high-risk histological subtypes of gastrointestinal stromal tumor, promotes GIST progression. | Radiol Oncol | 2026 | 42704035 | PubTator, text mining | PubMed |
| Anticancer effects of alpha-helical peptide epinecidin-1 and its variants in combination with doxorubicin. | Med Oncol | 2026 | 42484926 | PubTator, text mining | PubMed |
| Single-cell and spatial transcriptomics reveal lactate-active epithelial-immune cell crosstalk that reprograms the immune microenvironment in colorectal cancer. | Transl Oncol | 2026 | 42320170 | PubTator, text mining | PubMed |
| A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma. | Clin Cancer Res | 2026 | 42268288 | PubTator, text mining | PubMed |
| The EphA3 Antibody Enhances CD47 Antibody-Mediated Phagocytosis by Repolarizing M2-Like Tumor-Associated Macrophages in a Preclinical Model of Recurrent Head and Neck Cancer. | Onco Targets Ther | 2026 | 42164995 | PubTator, text mining | PubMed |
| Functional significance of miR-218 in lung cancer. | J Cancer Metastasis Treat | 2026 | 41924446 | PubTator, text mining | PubMed |
| Reassessing Transketolase Assays: Methodological Considerations for Detecting Functional Thiamine Deficiency. | Ann N Y Acad Sci | 2026 | 41870883 | PubTator, text mining | PubMed |
| BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations. | Mol Biomed | 2026 | 41807883 | PubTator, text mining | PubMed |
| CBX3:IL1RN Reflects Distinct Cellular States That Defines the Clinical Outcome of Oral Squamous Cell Carcinoma. | Cancer Med | 2026 | 41803005 | PubTator, text mining | PubMed |
| Integrin αvβ3 is a Potential Therapeutic Target in Cholangiocarcinoma. | Int J Med Sci | 2026 | 41799774 | PubTator, text mining | PubMed |
1 to 10 of 1,673
See all 1,673 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2042
GET https://conductscience.org/api/genes/v1/2042/patents?page=2